Heparin and low molecular weight heparin decrease nitric oxide production by human polymorphonuclear cells

Archives of Medical Research

Volumn 30, Issue 2, 1999, Pages 116-119

  Beltrán, Amada E ^a   Concepción, Francisco ^b   Manzanares, Dahis ^c   Garrido, Gabino ^a   Glaria, Luis A ^a   Rojas, Armando ^a  

^a Laboratorio Central de Farmacologia   (Cuba)

^b Departamento de Analisis   (Cuba)

^c Ctro de Invest Metalurgicas   (Cuba)

Author keywords

Heparin; Nitric oxide (NO); Polymorphonuclear neutrophil leukocytes (PMN)

Indexed keywords

FORMYLMETHIONYLLEUCYLPHENYLALANINE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NITRIC OXIDE;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUTROPHIL;

HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; METHEMOGLOBIN; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; NITRIC OXIDE;

EID: 0033027473     PISSN: 01880128     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-0128(99)00004-4     Document Type: Article

References (25)

1. Wright C.D., Muelsh A., Busse R., Osswald H. Generation of nitric oxide by human neutrophils. Biochem Biophys Res Commun. 160:1989;813.
2. Carreras M.C., Pargament G.A., Catz S.D., Poderoso J.J., Boveris A. Kinetics of nitric oxide and hydrogen peroxide production and formation of peroxynitrite during the respiratory burst of human neutrophils. FEBS Lett. 314:1994;5.
3. Wagner J.G., Ganey P.E., Roth R.A. Nitric oxide is not involved in hepatocyte killing by neutrophils activated by N-formyl-methionyl-leucylphenylalanine or phorbol myristate acetate in vitro. Hepatology. 23:1996;803.
4. Tyrrell D.J., Kilfeather S., Page C.P. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. TIPS. 16:1995;198.
5. Ley K., Cerrito M., Arfors K.E. Sulfated polysaccharides inhibits leukocytes rolling in rabbit mesentery venules. Am J Physiol. 260:1991;1667.
6. Bazzoni G., Beltrán-Núñez A., Mascellani G., Bianchini P., Dejana E., Del Maschio A. Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med. 121:1993;268.
7. Cerletti C., Rajtar G., Marchi E., de Gaetano G. Interaction between glycosaminoglycans, platelets and leukocytes. Semin Thromb Hemost. 20:1994;245.
8. Bøyum A. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1 g gravity field. Scand J Clin Lab Invest. 21:1968;5.
9. Allavena P., Paganin C., Martin-Padura I., Gaboli M., Dejana E., Marchisio P.C., Mantovani A. Molecules and structures involved in the adhesion of natural killer cells to vascular endothelium. J Exp Med. 173:1991;439.
10. Murphy M.E., Noack E. Nitric oxide assay using hemoglobin method. Methods Enzymol. 233:1994;240.
11. Palacios M., Padrón J., Glaria L., Rojas A., Delgado R., Knowles R., Moncada S. Chlorpromazine inhibits both the constitutive nitric oxide synthase and the induction of nitric oxide synthase after LPS challenge. Biochem Biophys Res Commun. 196(1):1993;280.
12. Arfors K.E., Ley K. Sulfated polysaccharides in inflammation. J Lab Clin Med. 121:1993;201.
13. Willenborg D.O., Parish C.R. Inhibition of allergic encephalomyelitis in rats by treatment with sulfated polysaccharides. J Immunol. 140:1988;3401.
14. Gorski A., Wasik M., Nowaczyk M., Korczak-Kowalska G. Immunomodulating activity of heparin. FASEB J. 5:1991;2287.
15. Nelson R.M., Cecconi O., Roberts W.G., Aruffo A., Linhardt R.J., Bevilacqua M.P. Heparin oligosaccharides bind L and P-selectin and inhibit acute inflammation. Blood. 82(11):1993;3253.
16. Moncada S., Higgs E.A. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 9:1995;1319.
17. Upchurch G.R. Jr., Welch G.N., Freedman J.E., Fabian A.J., Pigazzi A., Scribner A.M., Alpert C.S., Keaney J.F. Jr., Loscalzo J. High-dose heparin decreases nitric oxide production by cultured bovine endothelial cells. Circulation. 95:1997;2115.
18. Li J.M., Hajarizadeh H., La Rosa C.A., Rohrer M.J., Vander Salm T.J., Cutler B.S. Heparin and protamine stimulate the production of nitric oxide. J Cardiovasc Surg (Torino). 37:1996;445.
19. 2+-independent nitric oxide synthase activity in human lung after cardiopulmonary bypass. Thorax. 50:1995;403.
20. Prondzinsky R., Muller-Werdan U., Pilz G., Witthaut R., Stabenow I., Werdan K., Zerkowski H.R. Systemic inflammatory reactions to extracorporeal therapy measures. II. Cardiopulmonary bypass. Wien Klin Wochenschr. 109:1997;346.
21. Weerwind P.W., Maessen J.G., van Tits L.J., Stad R.K., Fransen E.J., de Jong D.S., Penn O.C. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. J Thorac Cardiovasc Surg. 110:1995;1633.
22. Lundblad R., Moen O., Fosse E. Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 63:1997;1361.
23. Moen O., Hogasen K., Fosse E., Dregelid E., Brockmeier V., Venge P., Harboe M., Mollnes T.E. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 63:1997;105.
24. Dobosz M., Mionskowska L., Dobrowolski S., Dymecki D., Makarewicz W., Hrabowska M., Wajda Z. Is nitric oxide and heparin treatment justified in inflammatory bowel disease? An experimental study. Scand J Clin Lab Invest. 56:1996;657.
25. Collins R., Scrimgeour A., Yusuf S., Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic and urologic surgery. N Engl J Med. 318:1988;1162.